Anja L Gawlitza1, Johanna Speith1, Jenny Rinke1, Roman Sajzew2, Elena K Müller1, Vivien Schäfer1, Andreas Hochhaus1, Thomas Ernst3. 1. Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. 2. Otto Schott Institute of Materials Research, Friedrich Schiller University, Jena, Germany. 3. Abteilung Hämatologie und Internistische Onkologie, Klinik für Innere Medizin II, Universitätsklinikum Jena, Am Klinikum 1, 07747, Jena, Germany. thomas.ernst@med.uni-jena.de.
Abstract
PURPOSE: Molecular mechanisms of response to hypomethylating agents in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) still remain largely unknown. Therefore, the effects of 5-Azacytidine (Aza) on clonal architecture and DNA methylation were investigated in this study. METHODS: Using next-generation sequencing (NGS), 30 myeloid leukemia-associated genes were analyzed in 15 MDS/CMML patients with excellent response to Aza. Effects on methylation levels were analyzed by quantitative methylation analysis using pyrosequencing for the global methylation marker LINE-1 in patients and myeloid cell lines. Various myeloid cell lines and a healthy cohort were screened for methylation levels in 23 genes. Selected targets were verified on the MDS/CMML cohort. RESULTS: The study presented here showed a stable variant allele frequency and stable global methylation levels in responding patients. A significant demethylation of EZH2 and NOTCH1 was revealed in patients with Aza response. CONCLUSIONS: A response to Aza is not associated with eradication of malignant clones, but rather with a stabilization of the clonal architecture. We suggest changes in CpG methylation levels of EZH2 and NOTCH1 as potential targets of epigenetic response to Aza treatment which may also serve as useful biomarkers after clinical evaluation.
PURPOSE: Molecular mechanisms of response to hypomethylating agents in patients with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) still remain largely unknown. Therefore, the effects of 5-Azacytidine (Aza) on clonal architecture and DNA methylation were investigated in this study. METHODS: Using next-generation sequencing (NGS), 30 myeloid leukemia-associated genes were analyzed in 15 MDS/CMMLpatients with excellent response to Aza. Effects on methylation levels were analyzed by quantitative methylation analysis using pyrosequencing for the global methylation marker LINE-1 in patients and myeloid cell lines. Various myeloid cell lines and a healthy cohort were screened for methylation levels in 23 genes. Selected targets were verified on the MDS/CMML cohort. RESULTS: The study presented here showed a stable variant allele frequency and stable global methylation levels in responding patients. A significant demethylation of EZH2 and NOTCH1 was revealed in patients with Aza response. CONCLUSIONS: A response to Aza is not associated with eradication of malignant clones, but rather with a stabilization of the clonal architecture. We suggest changes in CpG methylation levels of EZH2 and NOTCH1 as potential targets of epigenetic response to Aza treatment which may also serve as useful biomarkers after clinical evaluation.
Authors: Allen S Yang; Marcos R H Estécio; Ketan Doshi; Yutaka Kondo; Eloiza H Tajara; Jean-Pierre J Issa Journal: Nucleic Acids Res Date: 2004-02-18 Impact factor: 16.971
Authors: Vivien Schäfer; Jana Ernst; Jenny Rinke; Nils Winkelmann; James F Beck; Andreas Hochhaus; Bernd Gruhn; Thomas Ernst Journal: J Cancer Res Clin Oncol Date: 2016-05-11 Impact factor: 4.553
Authors: Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman Journal: Lancet Oncol Date: 2009-02-21 Impact factor: 41.316
Authors: Jane Merlevede; Nathalie Droin; Tingting Qin; Kristen Meldi; Kenichi Yoshida; Margot Morabito; Emilie Chautard; Didier Auboeuf; Pierre Fenaux; Thorsten Braun; Raphael Itzykson; Stéphane de Botton; Bruno Quesnel; Thérèse Commes; Eric Jourdan; William Vainchenker; Olivier Bernard; Noemie Pata-Merci; Stéphanie Solier; Velimir Gayevskiy; Marcel E Dinger; Mark J Cowley; Dorothée Selimoglu-Buet; Vincent Meyer; François Artiguenave; Jean-François Deleuze; Claude Preudhomme; Michael R Stratton; Ludmil B Alexandrov; Eric Padron; Seishi Ogawa; Serge Koscielny; Maria Figueroa; Eric Solary Journal: Nat Commun Date: 2016-02-24 Impact factor: 14.919
Authors: Sonja Zeilinger; Brigitte Kühnel; Norman Klopp; Hansjörg Baurecht; Anja Kleinschmidt; Christian Gieger; Stephan Weidinger; Eva Lattka; Jerzy Adamski; Annette Peters; Konstantin Strauch; Melanie Waldenberger; Thomas Illig Journal: PLoS One Date: 2013-05-17 Impact factor: 3.240
Authors: Michaela Dostalova Merkerova; Jiri Klema; David Kundrat; Katarina Szikszai; Zdenek Krejcik; Andrea Hrustincova; Iva Trsova; Anh Vu LE; Jaroslav Cermak; Anna Jonasova; Monika Belickova Journal: Cancer Genomics Proteomics Date: 2022 Mar-Apr Impact factor: 4.069
Authors: Pavla Koralkova; Monika Belickova; David Kundrat; Michaela Dostalova Merkerova; Zdenek Krejcik; Katarina Szikszai; Monika Kaisrlikova; Jitka Vesela; Pavla Vyhlidalova; Jan Stetka; Alzbeta Hlavackova; Jiri Suttnar; Patrik Flodr; Jan Stritesky; Anna Jonasova; Jaroslav Cermak; Vladimir Divoky Journal: Cancers (Basel) Date: 2021-04-30 Impact factor: 6.639